This observational study aims to better understand how certain proteins (biomarkers) in your body tissues relate to the success of your transplant and the effectiveness of medications used to prevent rejection. Researchers want to see if these biomarkers can help explain how anti-rejection drugs work and the processes that lead to rejection or a rejection-free outcome. The study is looking for 1200 people who have received an organ transplant (abdominal, thoracic) or a bone marrow transplant at the University of Pittsburgh Medical Center. The main goal is to see how often transplant rejection occurs within 90 days after your transplant. The study is currently unclear on its recruitment status.

Study design

This is an observational study, meaning researchers will collect information without giving any specific treatments. It plans to include 1200 participants.

What's involved

You may be asked to provide blood samples during your regular clinical tests, up to 15 ml as many as 7 times in the first year, and then less often. You may also be asked to provide up to 5 ml of saliva no more than four times.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome of rejection is measured at 90 days post-transplantation. Blood samples will be collected indefinitely to assess biomarker stability.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.